RENTON HOLLINGS 4

What Happened

• Renton Hollings, a director of AnaptysBio (ANAB), reported multiple derivative transactions on April 20, 2026 consisting of disposals to the issuer and concurrent acquisitions of options (all at $0.00). The reported acquisitions total options covering 107,320 underlying shares (aggregate of the A entries). No cash was paid or received; these entries reflect option adjustments tied to a corporate separation/spin-off.

Key Details

• Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (timely).
• Transaction type: Derivative adjustments/awards (dispositions to issuer paired with new option grants), price reported $0.00; total underlying shares acquired via options: 107,320.
• Shares/position after transaction: The filing reports the newly adjusted option grants; it does not show a cash sale or open-market trade of common stock.
• Notable footnotes:
  • F1: These adjustments resulted from a pro rata distribution under the Separation and Distribution Agreement with First Tracks — each existing option was split/adjusted into options for First Tracks and for AnaptysBio, producing the reported AnaptysBio option awards.
  • F2: Some option(s) are fully vested and exercisable.
  • F3: Other option(s) vest 1/12 monthly beginning Feb 6, 2026, subject to continued service.

Context

• This filing documents option adjustments due to a corporate separation, not an open-market buy or sale. Such administrative option reallocations are common after spin-offs and do not necessarily signal the insider buying or selling stock for personal investment reasons. For retail investors, purchases or sales of common stock are typically more indicative of insider sentiment than post-transaction option adjustments.